Search

Displaying results 2261 - 2270 of 4691 in total
  1. Drug

    AZD2315

    go.drugbank.com/drugs/DB06540
    Experimental

    The drug AZD2315, an immunosuppressant developed by AstraZeneca, was in Phase 1 clinical trials for the treatment of rheumatoid arthritis but was discontinued during this phase

  2. Drug

    Paclitaxel docosahexaenoic acid

    go.drugbank.com/drugs/DB05297
    Investigational

    A combination of docosahexaenoic Acid (a natural fatty acid) and paclitaxel (an anticancer drug) being studied in the treatment of cancer. It is a type of mitotic inhibitor.

  3. Drug

    Iodine povacrylex

    go.drugbank.com/drugs/DB09537
    Approved

    Prolonged skin exposure could cause skin defatting manifested by the following signs/symptoms; localized redness, itching, drying and cracking of skin.

  4. Drug

    Colistin

    go.drugbank.com/drugs/DB00803
    ApprovedInvestigational

    Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally.

  5. Drug

    Dostarlimab

    go.drugbank.com/drugs/DB15627
    ApprovedInvestigational

    [L33320] PD-1 receptors are found on T-cells and, when activated, serve to inhibit immune responses - some cancers leverage this system by overexpressing PD-1 ligands, thereby effectively inhibiting the … In April 2021, dostarlimab was granted accelerated approval by the FDA - as GlaxoSmithKline's dostarlimab-gxly (Jemperli) - for the treatment of adult patients with recurrent or advanced mismatch repair

  6. Drug

    Varicella zoster vaccine (live/attenuated)

    go.drugbank.com/drugs/DB10318
    ApprovedInvestigational

    This is a significant improvement over its predecessor, Zostavax, which reduces the risk of shingles by only 51% and the risk of post-herpetic neuralgia by 67% [A31349]. … First approved in May 2006 by the Food and Drug Administration, Zostavax was the first vaccine available for the prevention of shingles.

  7. Drug

    XL281

    go.drugbank.com/drugs/DB05190
    Investigational

    XL281 is a specific inhibitor of RAF kinases, including the mutant form of B-RAF, which is activated in 60 percent of melanomas, 24-44 percent of thyroid cancers, and 9 percent of colon cancers.

  8. Drug

    Typhoid Vaccine Live

    go.drugbank.com/drugs/DB11050
    ApprovedInvestigational

    The vaccine prevents the development of typhoid fever, an acute, febrile enteric disease caused by *Salmonella typhi* by inducing a local immune response in the intestinal tract.

  9. Drug

    AdimrSC-2f

    go.drugbank.com/drugs/DB16436
    Investigational

    The AdimrSC-2f (SARS-CoV-2) vaccine is developed through Adimmune Corporation, the only influenza vaccine manufacturer with both EU GMP and US FDA certification in Asia[L30553].

  10. Drug

    Forigerimod

    go.drugbank.com/drugs/DB12490
    Investigational

    Forigerimod is under investigation for the treatment of Lupus Erythematosus, Systemic.

    Categories: Ribonucleoprotein, U1 Small Nuclear